천식 치료제 시장 규모, 점유율, 성장 분석 : 약물 종류별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Asthma Drugs Market size was valued at USD 22.52 Billion in 2024 and is poised to grow from USD 23.92 Billion in 2025 to USD 38.85 Billion by 2033, growing at a CAGR of 6.22% during the forecast period (2026-2033).

The global asthma drugs market is primarily driven by the increasing prevalence of respiratory diseases, fueling ongoing demand for effective therapies. This market includes inhaled corticosteroids, bronchodilators, combination inhalers, and a growing range of monoclonal biologics designed to manage inflammation and minimize exacerbations, as uncontrolled asthma leads to higher hospitalizations and healthcare expenses. The evolution of treatment strategies has moved from short-acting bronchodilators to long-term anti-inflammatory solutions. A significant trend in this sector is the rise of technological and therapeutic innovations, enhancing treatment precision and patient adherence. Improvements in biologic therapies prompt wider acceptance among payers and earlier prescriptions by clinicians, resulting in increased usage and revenue. Opportunities for market growth also arise with biosimilars, value-based care contracts, and integrated digital solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Asthma Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Asthma Drugs Market Segments Analysis

Global asthma drugs market is segmented by drug class, delivery route, end-user and region. Based on drug class, the market is segmented into bronchodilators, corticosteroids (ICS), biologics (dupixent, xolair) and leukotriene modifiers. Based on delivery route, the market is segmented into inhalation (MDI, DPI, nebulizer), oral and injectable. Based on end-user, the market is segmented into hospitals, clinics and retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Asthma Drugs Market

The Global Asthma Drugs market is significantly driven by heightened patient awareness and proactive screening, leading to an increase in diagnosis rates and earlier initiation of treatment. This development not only broadens the population requiring intervention but also sustains the demand for a range of therapeutic options. Advocacy groups and educational initiatives play a crucial role in enhancing adherence to asthma management and medication, effectively supporting clinicians in prescribing both maintenance and advanced therapies. Furthermore, the recognition of asthma medications aids in promoting stable therapy use, spurring pharmaceutical investments in innovative formulations and delivery systems, and encouraging healthcare facilities to establish comprehensive asthma care pathways centered around pharmacological solutions.

Restraints in the Global Asthma Drugs Market

The Global Asthma Drugs market faces significant constraints primarily due to the high costs associated with new medications, which often render them unaffordable for many patients. Limited reimbursement options further restrict access, as healthcare systems tend to favor lower-cost alternatives, leading to stringent eligibility criteria for the use of higher-priced drugs. This situation creates challenges for healthcare providers trying to prescribe these newer therapies and for patients attempting to access them. Consequently, these barriers to entry deter pharmaceutical companies from promoting their products in certain regions, ultimately reducing the commercial viability and innovation potential within the asthma treatment landscape.

Market Trends of the Global Asthma Drugs Market

The Global Asthma Drugs market is witnessing a significant trend towards the rise of biologic therapies, fundamentally transforming the treatment landscape for patients suffering from severe and uncontrolled asthma. These advanced therapies facilitate phenotype-driven treatment approaches that effectively address previously unmet medical needs. As manufacturers prioritize unique market positioning, strategic partnerships, and innovative investments, the development of companion diagnostics is becoming increasingly important. This shift not only alters prescribing practices but also supports the emergence of premium pricing models linked to proven clinical benefits. Consequently, payers and providers are focusing more on long-term outcomes and the disease-modifying potential of treatments, enhancing the prioritization of drugs in development pipelines.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Asthma Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Bronchodilators
  • SABA (Albuterol)
  • LABA (Salmeterol)
• Corticosteroids (ICS)
• Biologics (Dupixent, Xolair)
• Leukotriene Modifiers

Global Asthma Drugs Market Size by Delivery Route & CAGR (2026-2033)

• Market Overview
• Inhalation (MDI, DPI, Nebulizer)
• Oral
• Injectable

Global Asthma Drugs Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Retail Pharmacies

Global Asthma Drugs Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific

Global Asthma Drugs Market Size & CAGR (2026-2033)

• North America (Drug Class, Delivery Route, End-User, Region)
  • US
  • Canada
• Europe (Drug Class, Delivery Route, End-User, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Delivery Route, End-User, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Delivery Route, End-User, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Delivery Route, End-User, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca (Pulmicort, Symbicort)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (Advair, Breo)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Spiriva)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Xolair - co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Xolair)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (Dupixent - co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron (Dupixent)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical (ProAir)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunovion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations